JP2022533538A5 - - Google Patents

Info

Publication number
JP2022533538A5
JP2022533538A5 JP2021565723A JP2021565723A JP2022533538A5 JP 2022533538 A5 JP2022533538 A5 JP 2022533538A5 JP 2021565723 A JP2021565723 A JP 2021565723A JP 2021565723 A JP2021565723 A JP 2021565723A JP 2022533538 A5 JP2022533538 A5 JP 2022533538A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021565723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533538A (ja
JP7686571B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031749 external-priority patent/WO2020227457A1/en
Publication of JP2022533538A publication Critical patent/JP2022533538A/ja
Publication of JP2022533538A5 publication Critical patent/JP2022533538A5/ja
Priority to JP2024131038A priority Critical patent/JP2024170410A/ja
Application granted granted Critical
Publication of JP7686571B2 publication Critical patent/JP7686571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021565723A 2019-05-08 2020-05-07 T細胞媒介性免疫を調節するための材料及び方法 Active JP7686571B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024131038A JP2024170410A (ja) 2019-05-08 2024-08-07 T細胞媒介性免疫を調節するための材料及び方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962844976P 2019-05-08 2019-05-08
US201962844966P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US62/844,959 2019-05-08
US62/844,966 2019-05-08
US62/844,970 2019-05-08
US62/844,976 2019-05-08
US62/844,995 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024131038A Division JP2024170410A (ja) 2019-05-08 2024-08-07 T細胞媒介性免疫を調節するための材料及び方法

Publications (3)

Publication Number Publication Date
JP2022533538A JP2022533538A (ja) 2022-07-25
JP2022533538A5 true JP2022533538A5 (cg-RX-API-DMAC7.html) 2023-05-16
JP7686571B2 JP7686571B2 (ja) 2025-06-02

Family

ID=73051172

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021565723A Active JP7686571B2 (ja) 2019-05-08 2020-05-07 T細胞媒介性免疫を調節するための材料及び方法
JP2024131038A Pending JP2024170410A (ja) 2019-05-08 2024-08-07 T細胞媒介性免疫を調節するための材料及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024131038A Pending JP2024170410A (ja) 2019-05-08 2024-08-07 T細胞媒介性免疫を調節するための材料及び方法

Country Status (22)

Country Link
US (2) US11667712B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965818A4 (cg-RX-API-DMAC7.html)
JP (2) JP7686571B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220017892A (cg-RX-API-DMAC7.html)
CN (1) CN113966231B (cg-RX-API-DMAC7.html)
AU (1) AU2020267504A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022089A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139508A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002905A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021015998A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210548A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000229A (cg-RX-API-DMAC7.html)
EC (1) ECSP21087921A (cg-RX-API-DMAC7.html)
IL (1) IL287817A (cg-RX-API-DMAC7.html)
JO (1) JOP20210297A1 (cg-RX-API-DMAC7.html)
MA (1) MA55903A (cg-RX-API-DMAC7.html)
MX (1) MX2021013532A (cg-RX-API-DMAC7.html)
PE (1) PE20220763A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552790A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112021QA (cg-RX-API-DMAC7.html)
TW (1) TW202108618A (cg-RX-API-DMAC7.html)
WO (1) WO2020227457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
JP7686571B2 (ja) 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用
CA3173268A1 (en) * 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
US12076413B2 (en) 2020-10-28 2024-09-03 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
CA3211114A1 (en) * 2021-02-16 2022-08-25 Janssen Biotech, Inc. Materials and methods for enhanced linker targeting
WO2022180271A1 (en) 2021-02-26 2022-09-01 LAVA Therapeutics N.V. Antibodies that bind CD123 and gamma-delta T cell receptors
JP2026526851A (ja) * 2023-07-26 2026-08-10 ヤンセン バイオテツク,インコーポレーテツド 細胞増殖のための材料及び方法
AU2024379650A1 (en) * 2023-11-15 2026-06-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Trgv9 binding proteins and medical use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック, インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2012018767A2 (en) 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
LT2748201T (lt) * 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
DK3189081T3 (da) 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
EP3560955A4 (en) 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
BR112020023508A2 (pt) 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
JP7686571B2 (ja) 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
CA3173268A1 (en) 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
PE20231517A1 (es) 2020-03-13 2023-09-28 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33
US12076413B2 (en) 2020-10-28 2024-09-03 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity

Similar Documents

Publication Publication Date Title
JP2021533726A5 (cg-RX-API-DMAC7.html)
JP2021515565A5 (cg-RX-API-DMAC7.html)
JP2021516973A5 (cg-RX-API-DMAC7.html)
JP2021516974A5 (cg-RX-API-DMAC7.html)
CN110536903A (zh) 抗ox40抗体及其用途
JP2021515568A5 (cg-RX-API-DMAC7.html)
JP2021516975A5 (cg-RX-API-DMAC7.html)
JP2021515566A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
CN112135626A (zh) 抗tigit抗体及其用途
JP2020514277A5 (cg-RX-API-DMAC7.html)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2022523442A5 (cg-RX-API-DMAC7.html)
JP2018510636A5 (cg-RX-API-DMAC7.html)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2020522280A5 (cg-RX-API-DMAC7.html)
RU2019104980A (ru) Анти-icos антитела
JP2020522281A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2020515277A5 (cg-RX-API-DMAC7.html)
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2020513759A5 (cg-RX-API-DMAC7.html)
JP2023518153A5 (cg-RX-API-DMAC7.html)
CN115812081A (zh) 抗ctla-4抗体及其用途
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症